Glenmede Trust CO Na Macrogenics Inc Transaction History

Glenmede Trust CO Na

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$19.41 - $26.0 $2,853 - $3,822	-147 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$24.69 - $31.6 $5,184 - $6,636	-210 Reduced 58.82%	147 $3,000
Q2 2020 Aug 14, 2020	SELL	$5.2 - $29.12 $3,120 - $17,472	-600 Reduced 62.7%	357 $9,000
Q4 2019 Feb 12, 2020	BUY	$7.95 - $12.27 $1,367 - $2,110	172 Added 21.91%	957 $10,000
Q3 2019 Nov 14, 2019	SELL	$12.44 - $17.48 $2,637 - $3,705	-212 Reduced 21.26%	785 $10,000
Q1 2019 May 14, 2019	BUY	$11.11 - $25.6 $11,076 - $25,523	997 New	997 $17,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $224M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

Stay updated on Glenmede Trust CO Na with notifications on news.